Research and Development (R&D) expenses: R&D expenses were $22.9 million for the first quarter of 2025, compared to $33.7 million for the first quarter of 2024. General and Administrative (G&A) ...

SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

The JADE study will be evaluating BI 1584862, an investigational oral compound that targets inflammation and preserves ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET. Company Participants. Stephanie Fagan - Chief Corporate Affairs Officer Rob Bar ...

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

A groundbreaking trial found vagus nerve stimulation combined with therapy may fully eliminate PTSD symptoms in patients.

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 12.92%, which has investors questioning if this is right time to ...

At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Eye Care Network caught up with Jogin Desai. Dr. Desai is the founder of Eyestem Research, a biotechnology ...

A very low-carb diet significantly improved the pancreas’s ability to produce insulin in people with mild Type 2 diabetes ...

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...